tDCS in Post-COVID Syndrome: Comparison of Two Targets

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-01

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of this study is to compare the effect of two non-invasive neuromodulation targets in patients meeting WHO criteria for the post-COVID condition. A randomized, parallel, double-blind study will be conducted. Patients will receive 15 neuromodulation sessions through transcranial electrical stimulation for 3 weeks, associated with cognitive stimulation during therapy. The main objective will be to evaluate the change in physical fatigue. As secondary objectives, changes in cognition, depression, pain, quality of sleep and quality of life will be evaluated. The objective of this study is to evaluate the effect of two targets (left dorsolateral prefrontal and M1) of the neuromodulation intervention, together with cognitive stimulation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19

NCT05252481

COVID-19

COMPLETED NA

Neuromodulation in COVID-19 Patients

NCT04808284

COVID-19

COMPLETED PHASE1/PHASE2

tDCS in the Management of Post-COVID Disorders

NCT06074848

Long COVID

RECRUITING PHASE2

Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS

NCT05289115

Coronavirus COVID-19 Respiratory Infection

UNKNOWN NA

Transcranial Direct Current Stimulation (tDCS) for Post COVID-19 Fatigue

NCT04876417

Post Covid-19 Patients

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Post-COVID-19 Syndrome Post COVID-19 Condition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Left dorsolateral prefrontal cortex

15 sessiones of anodal tDCS over the left dorsolateral prefrontal cortex (2 mA, 20 minutes) associated with cognitive training.

Group Type ACTIVE_COMPARATOR

transcranial current direct stimulation

Intervention Type DEVICE

Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)

Left M1

15 sessiones of anodal tDCS over the left M1 (2 mA, 20 minutes) associated with cognitive training.

Group Type ACTIVE_COMPARATOR

transcranial current direct stimulation

Intervention Type DEVICE

Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcranial current direct stimulation

Transcranial electrical stimulation over two different brain regions associated with cognitive training. 15 sesions in 3 weeks (5 days/week)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of COVID-19 at least 6 months before the participation in the study.
* Diagnosis of post-COVID condition according to WHO criteria.
* Age 18-65 years.
* Spanish as native language.
* Sign of written informed consent.

Exclusion Criteria

* History of stroke
* History of traumatic brain injury or central nervous system infection
* Diagnosis of other neurological or medical disorder that could impact on fatigue.
* Diagnosis of active psychiatric disorder potentially impacting on fatigue or cognitive function.
* Chemotherapy or radiotherapy for cancer.
* Severe sensory deficits (e.g. visual loss) that could limit assessments included int the study protocol.
* Taking drugs or uncontrolled medical disorder potentially causing or worsening fatigue. Specifically, uncontrolled adrenal insufficiency, miastenic syndromes, thyroid disorders, cardiac failure, chronic kidney disorders and neurodegenerative disorders are excluded.
* History of abuse of alcohol or other toxics.
* Any contraindication for transcranial electric stimulation: epilepsy, pregnancy, metallic implants, brain devices, pacemakers, head injuries).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No